October 13, 2021 -- Twist Bioscience and the Broad Institute have created a custom next-generation sequencing (NGS) target enrichment exome panel to be used to research cancer and rare and inherited disease genes.
Twist will market the exome panel as the Twist Alliance Clinical Research Exome. The offering will help support the Broad Institute's genomics platform and was designed using validated data from clinical patient samples, Twist said.
The panel leverages Twist's NGS platform to customize content, resulting in a comprehensive survey of the exome with supplemental enrichment of clinically relevant areas of the genome related to cancer and rare and inherited diseases. By leveraging the uniformity of Twist NGS probes, the assay enables a per sample cost and throughput efficiency that Broad has already leveraged to process more than 250,000 samples to date.